223 related articles for article (PubMed ID: 23956301)
21. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice.
Poo H; Pyo HM; Lee TY; Yoon SW; Lee JS; Kim CJ; Sung MH; Lee SH
Int J Cancer; 2006 Oct; 119(7):1702-9. PubMed ID: 16646080
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
23. Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation.
Abdelaziz MO; Ossmann S; Kaufmann AM; Leitner J; Steinberger P; Willimsky G; Raftery MJ; Schönrich G
Front Immunol; 2019; 10():1776. PubMed ID: 31417555
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
25. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
[TBL] [Abstract][Full Text] [Related]
26. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.
Delgado FG; Martínez E; Céspedes MA; Bravo MM; Navas MC; Cómbita Rojas AL
Immunology; 2009 Apr; 126(4):523-34. PubMed ID: 18778290
[TBL] [Abstract][Full Text] [Related]
27. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8
Krishna S; Ulrich P; Wilson E; Parikh F; Narang P; Yang S; Read AK; Kim-Schulze S; Park JG; Posner M; Wilson Sayres MA; Sikora A; Anderson KS
Cancer Res; 2018 Nov; 78(21):6159-6170. PubMed ID: 30154146
[TBL] [Abstract][Full Text] [Related]
28. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
29. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
30. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
31. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
[TBL] [Abstract][Full Text] [Related]
32. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
33. High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes.
Cicchini L; Blumhagen RZ; Westrich JA; Myers ME; Warren CJ; Siska C; Raben D; Kechris KJ; Pyeon D
Sci Rep; 2017 Jun; 7(1):3633. PubMed ID: 28623356
[TBL] [Abstract][Full Text] [Related]
34. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
35. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
36. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
[TBL] [Abstract][Full Text] [Related]
37. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
38. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells.
Hengel H; Esslinger C; Pool J; Goulmy E; Koszinowski UH
J Gen Virol; 1995 Dec; 76 ( Pt 12)():2987-97. PubMed ID: 8847504
[TBL] [Abstract][Full Text] [Related]
39. Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes.
Heise MT; Connick M; Virgin HW
J Exp Med; 1998 Apr; 187(7):1037-46. PubMed ID: 9529320
[TBL] [Abstract][Full Text] [Related]
40. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape.
Hengel H; Lucin P; Jonjić S; Ruppert T; Koszinowski UH
J Virol; 1994 Jan; 68(1):289-97. PubMed ID: 8254740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
